Methotrexate pharmacokinetic is influenced by co-administration of cyclosporin in rheumatoid arthritis patients. Results from a randomized clinical trial

References

• Pincus T, Cronstein B, Braun J. Methotrexate-the anchor drug-an introduction. Clin Exp Rheumatol. 2010;28:1–2.
   PubMed Web of Science ®Google Scholar
• Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. Joint Bone Spine. 2019;86:301–307.
   PubMed Web of Science ®Google Scholar
• Braun J. Optimal administration and dosage of methotrexate. Clin Exp Rheumatol. 2010;28:46–51.
   PubMed Web of Science ®Google Scholar
• Bannwarth B, Pehourcq F, Schaeverbeke T, et al. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet. 1996;30:194–210.
   PubMed Web of Science ®Google Scholar
• van Roon EN, van de Laar MA. Methotrexate bioavailability. Clin Exp Rheumatol. 2010;28:27–32.
   PubMed Web of Science ®Google Scholar
• Goodman S. Measuring methotrexate polyglutamates. Clin Exp Rheumatol. 2010;28:24–26.
   PubMed Web of Science ®Google Scholar
• Mohamed HJ, Sorich MJ, Kowalski SM, et al. The role and utility of measuring red blood cell methotrexate polyglutamate concentrations in inflammatory arthropathies—a systematic review. Eur J Clin Pharmacol. 2015;71:411–423.
   PubMed Web of Science ®Google Scholar
• Danila MI, Hughes LB, Brown EE, et al. Measurement of erythrocyte methotrexate polyglutamate levels: ready for clinical use in rheumatoid arthritis? Curr Rheumatol Rep. 2010;12:342–347.
   PubMedGoogle Scholar
• American College of Rheumatology Subcommitee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. 2002 update. Arthritis Rheum. 2002;46:328–346.
   PubMedGoogle Scholar
• Chaudhuri K, Torley H, Madhok R. Disease-modifying anti-rheumatic drugs. Cyclosporin. Br J Rheumatol. 1997;36:1016–1021.
   PubMedGoogle Scholar
• Gremese E, Ferraccioli GF. Benefit/risk of cyclosporine in rheumatoid arthritis. Clin Exp Rheumatol. 2004;22:101–107.
   PubMed Web of Science ®Google Scholar
• Tugwell P, Bombardier C, Gent M, et al. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet. 1990;335:1051–1055.
   PubMed Web of Science ®Google Scholar
• Hazlewood GS, Barnabe C, Tomlinson G, et al. Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: a network meta-analysis. Cochrane Database Syst Rev. 2016;CD010227.
   PubMed Web of Science ®Google Scholar
• Hetland ML, Stengaard-Pedersen K, Junker P, et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. Arthritis Rheum. 2006;54:1401–1409.
   PubMed Web of Science ®Google Scholar
• Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The methotrexate-cyclosporine combination study group. N Engl J Med. 1995;333:137–141.
   PubMed Web of Science ®Google Scholar
• Stein CM, Pincus T, Yocum D, The Methotrexate-Cyclosporine Combination Study Group, et al. Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks: an open-label extension study. The methotrexate-cyclosporine combination study group. Arthritis Rheum. 1997;40:1843–1851.
   PubMed Web of Science ®Google Scholar
• Bentin J. Mechanism of action of cyclosporin in rheumatoid arthritis. Clin Rheumatol. 1995;14:22–25.
   PubMed Web of Science ®Google Scholar
• Choc MG. Bioavailability and pharmacokinetics of cyclosporine formulations: neoral vs. sandimmune. Int J Dermatol. 1997;36:1–6.
   PubMed Web of Science ®Google Scholar
• Arnett FC, Edworthy SM, Bloch DA, et al. The American rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–324.
   PubMed Web of Science ®Google Scholar
• Levey AS, Greene T, Kusek JW, et al. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol. 2000;11:155A.
   Google Scholar
• Hornung N, Ellingsen T, Attermann J, et al. Patients with rheumatoid arthritis treated with methotrexate (MTX): concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacy. J Rheumatol. 2008;35:1709–1715.
   PubMed Web of Science ®Google Scholar
• Godfrey C, Sweeney K, Miller K, et al. The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis. Br J Clin Pharmacol. 1998;46:369–376.
   PubMed Web of Science ®Google Scholar
• Fox RI, Morgan SL, Smith HT, et al. Combined oral cyclosporin and methotrexate therapy in patients with rheumatoid arthritis elevates methotrexate levels and reduces 7-hydroxymethotrexate levels when compared with methotrexate alone. Rheumatology (Oxford). 2003;42:989–994.
   PubMed Web of Science ®Google Scholar
• Bourré-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J Rheumatol. 2010;37:1416–1421.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Petrillo GF, Hamilton RA. Pharmacokinetics and renal function in patients with rheumatoid arthritis receiving a standard dose of oral weekly methotrexate: association with significant decreases in creatinine clearance and renal clearance of the drug after 6 months of therapy. J Rheumatol. 1995;1:38–40.
   Google Scholar
• Bressolle F, Bologna C, Edno L, et al. A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM. Eur J Clin Pharmacol. 1996;4:285–292.
   Google Scholar
• Dervieux T, Zablocki R, Kremer J. Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology (Oxford). 2010;49:2337–2345.
   PubMed Web of Science ®Google Scholar
• Kristensen K, Nielsen S, Karup Pedersen F, et al. Erythrocyte-methotrexate and disease activity in children treated with oral methotrexate for juvenile chronic arthritis. Scand J Rheumatol. 2000;29:187–189.
   PubMed Web of Science ®Google Scholar
• Lafforgue P, Monjanel-Mouterde S, Durand A, et al. Lack of correlation between pharmacokinetics and efficacy of low dose methotrexate in patients with rheumatoid arthritis. J Rheumatol. 1995;5:844–849.
   Google Scholar
• Eksborg S, Albertioni F, Beck O, et al. Methotrexate in rheumatoid arthritis–a limited sampling strategy for estimation of the area under the plasma concentration versus time curve. Ther Drug Monit. 1994;16:560–563.
   PubMed Web of Science ®Google Scholar
• Dalrymple JM, Stamp LK, O'Donnell JL, et al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2008;58:3299–3308.
   PubMed Web of Science ®Google Scholar